Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals

J.M. Trevillyan, E.E. Gardiner, R. K. Andrews, A. Maisa, A.C. Hearps, M. Al-Tamimi, S. M. Crowe, J. F. Hoy

Research output: Contribution to journalArticleResearchpeer-review

Abstract

HIV-positive patients are at increased risk for coronary artery disease (CAD); changes in platelet activation may play a role. This study was performed to determine if levels of soluble glycoprotein VI (sGPVI), a platelet-specific marker of activation, were different in HIV-positive patients compared with HIV-negative controls and further if levels were predictive of CAD in HIV. Twenty-four HIV-positive individuals (HIV cases) with CAD were compared with 46 age- and sex-matched HIV-positive controls without CAD and 41 HIV-negative controls (healthy controls). Platelet activation (represented by sGPVI level) was compared 12 months and 1 month prior to CAD diagnosis. sGPVI was quantified by ELISA. sGPVI levels were higher in HIV-positive subjects (combined) than healthy controls (122.5 ng/mL [interquartile ranges (IQR) 90.3–160.5] versus 84.7 ng/mL [IQR 48.6–119.5], p <0.001). Twelve months before the event, there was no difference in sGPVI between HIV cases and HIV controls (113.4 ng/mL [IQR 85.6–141.65] versus 128.0 ng/mL [IQR 96.6–179.4], p = 0.369). One month prior to the event, sGPVI was significantly lower in HIV cases compared with HIV controls (109.0 ng/mL [IQR 79.4–123.4] versus 133.9 ng/mL [IQR 112.7–171.9], p = 0.010). These results remained significant following adjustment for possible confounders. This work demonstrates that HIV infection is associated with higher sGPVI levels. A fall in sGPVI immediately prior to first coronary artery event may reflect a loss of negative-feedback mechanism and be an important pathological step in the development of symptomatic CAD, but further work is needed to confirm these findings and determine their clinical impact.

Original languageEnglish
Pages (from-to)301-304
Number of pages4
JournalPlatelets
Volume28
Issue number3
DOIs
Publication statusPublished - 3 Apr 2017

Keywords

  • Cardiovascular disease
  • HIV
  • soluble glycoprotein VI
  • Thrombosis

Cite this

@article{e55936af3cea4196b98c18f449566df5,
title = "Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals",
abstract = "HIV-positive patients are at increased risk for coronary artery disease (CAD); changes in platelet activation may play a role. This study was performed to determine if levels of soluble glycoprotein VI (sGPVI), a platelet-specific marker of activation, were different in HIV-positive patients compared with HIV-negative controls and further if levels were predictive of CAD in HIV. Twenty-four HIV-positive individuals (HIV cases) with CAD were compared with 46 age- and sex-matched HIV-positive controls without CAD and 41 HIV-negative controls (healthy controls). Platelet activation (represented by sGPVI level) was compared 12 months and 1 month prior to CAD diagnosis. sGPVI was quantified by ELISA. sGPVI levels were higher in HIV-positive subjects (combined) than healthy controls (122.5 ng/mL [interquartile ranges (IQR) 90.3–160.5] versus 84.7 ng/mL [IQR 48.6–119.5], p <0.001). Twelve months before the event, there was no difference in sGPVI between HIV cases and HIV controls (113.4 ng/mL [IQR 85.6–141.65] versus 128.0 ng/mL [IQR 96.6–179.4], p = 0.369). One month prior to the event, sGPVI was significantly lower in HIV cases compared with HIV controls (109.0 ng/mL [IQR 79.4–123.4] versus 133.9 ng/mL [IQR 112.7–171.9], p = 0.010). These results remained significant following adjustment for possible confounders. This work demonstrates that HIV infection is associated with higher sGPVI levels. A fall in sGPVI immediately prior to first coronary artery event may reflect a loss of negative-feedback mechanism and be an important pathological step in the development of symptomatic CAD, but further work is needed to confirm these findings and determine their clinical impact.",
keywords = "Cardiovascular disease, HIV, soluble glycoprotein VI, Thrombosis",
author = "J.M. Trevillyan and E.E. Gardiner and Andrews, {R. K.} and A. Maisa and A.C. Hearps and M. Al-Tamimi and Crowe, {S. M.} and Hoy, {J. F.}",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/09537104.2016.1237627",
language = "English",
volume = "28",
pages = "301--304",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",
number = "3",

}

Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals. / Trevillyan, J.M.; Gardiner, E.E.; Andrews, R. K.; Maisa, A.; Hearps, A.C.; Al-Tamimi, M.; Crowe, S. M.; Hoy, J. F.

In: Platelets, Vol. 28, No. 3, 03.04.2017, p. 301-304.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Decreased levels of platelet-derived soluble glycoprotein VI detected prior to the first diagnosis of coronary artery disease in HIV-positive individuals

AU - Trevillyan, J.M.

AU - Gardiner, E.E.

AU - Andrews, R. K.

AU - Maisa, A.

AU - Hearps, A.C.

AU - Al-Tamimi, M.

AU - Crowe, S. M.

AU - Hoy, J. F.

PY - 2017/4/3

Y1 - 2017/4/3

N2 - HIV-positive patients are at increased risk for coronary artery disease (CAD); changes in platelet activation may play a role. This study was performed to determine if levels of soluble glycoprotein VI (sGPVI), a platelet-specific marker of activation, were different in HIV-positive patients compared with HIV-negative controls and further if levels were predictive of CAD in HIV. Twenty-four HIV-positive individuals (HIV cases) with CAD were compared with 46 age- and sex-matched HIV-positive controls without CAD and 41 HIV-negative controls (healthy controls). Platelet activation (represented by sGPVI level) was compared 12 months and 1 month prior to CAD diagnosis. sGPVI was quantified by ELISA. sGPVI levels were higher in HIV-positive subjects (combined) than healthy controls (122.5 ng/mL [interquartile ranges (IQR) 90.3–160.5] versus 84.7 ng/mL [IQR 48.6–119.5], p <0.001). Twelve months before the event, there was no difference in sGPVI between HIV cases and HIV controls (113.4 ng/mL [IQR 85.6–141.65] versus 128.0 ng/mL [IQR 96.6–179.4], p = 0.369). One month prior to the event, sGPVI was significantly lower in HIV cases compared with HIV controls (109.0 ng/mL [IQR 79.4–123.4] versus 133.9 ng/mL [IQR 112.7–171.9], p = 0.010). These results remained significant following adjustment for possible confounders. This work demonstrates that HIV infection is associated with higher sGPVI levels. A fall in sGPVI immediately prior to first coronary artery event may reflect a loss of negative-feedback mechanism and be an important pathological step in the development of symptomatic CAD, but further work is needed to confirm these findings and determine their clinical impact.

AB - HIV-positive patients are at increased risk for coronary artery disease (CAD); changes in platelet activation may play a role. This study was performed to determine if levels of soluble glycoprotein VI (sGPVI), a platelet-specific marker of activation, were different in HIV-positive patients compared with HIV-negative controls and further if levels were predictive of CAD in HIV. Twenty-four HIV-positive individuals (HIV cases) with CAD were compared with 46 age- and sex-matched HIV-positive controls without CAD and 41 HIV-negative controls (healthy controls). Platelet activation (represented by sGPVI level) was compared 12 months and 1 month prior to CAD diagnosis. sGPVI was quantified by ELISA. sGPVI levels were higher in HIV-positive subjects (combined) than healthy controls (122.5 ng/mL [interquartile ranges (IQR) 90.3–160.5] versus 84.7 ng/mL [IQR 48.6–119.5], p <0.001). Twelve months before the event, there was no difference in sGPVI between HIV cases and HIV controls (113.4 ng/mL [IQR 85.6–141.65] versus 128.0 ng/mL [IQR 96.6–179.4], p = 0.369). One month prior to the event, sGPVI was significantly lower in HIV cases compared with HIV controls (109.0 ng/mL [IQR 79.4–123.4] versus 133.9 ng/mL [IQR 112.7–171.9], p = 0.010). These results remained significant following adjustment for possible confounders. This work demonstrates that HIV infection is associated with higher sGPVI levels. A fall in sGPVI immediately prior to first coronary artery event may reflect a loss of negative-feedback mechanism and be an important pathological step in the development of symptomatic CAD, but further work is needed to confirm these findings and determine their clinical impact.

KW - Cardiovascular disease

KW - HIV

KW - soluble glycoprotein VI

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84995475746&partnerID=8YFLogxK

U2 - 10.1080/09537104.2016.1237627

DO - 10.1080/09537104.2016.1237627

M3 - Article

VL - 28

SP - 301

EP - 304

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 3

ER -